This activity is jointly provided by Parkinson & Movement Disorder Alliance (PMD Alliance) and The Association of Movement Disorder Advanced Practice Providers (AMDAPP).

Advanced practice providers (APPs) in movement disorder care play a central role in managing Parkinson’s disease and related disorders, yet significant gaps remain between current and optimal practice. While most APPs possess foundational skills in assessment, diagnosis, and management of common movement disorders, variability exists in their exposure to advanced and emerging therapies, including device-based interventions such as Deep Brain Stimulation (DBS) programming and subcutaneous pump management. Gaps are also noted in differential diagnosis across the parkinsonism spectrum, management of complex neuropsychiatric comorbidities, and effective interdisciplinary communication and leadership within multidisciplinary teams. Rapid advancements in pharmacologic, rehabilitative, and procedural treatment strategies further widen this divide, requiring ongoing, specialized education. This CME activity is designed to close these gaps by delivering evidence-based updates, training in advanced diagnostic and therapeutic approaches, and skill-building in team-based care—aligning APP performance with optimal standards and improving the overall quality and effectiveness of patient care.

Estimated time to complete activity: 15 minutes

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by PMD Alliance.  PMD Alliance is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Continuing Medical Education

PMD Alliance designates this course for a maximum of 13.5 AMA PRA Category 1 Credit(s)™.  

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Educational Objectives

After completing this activity, the participant should be better able to:

• Develop advanced diagnostic skills to differentiate the parkinsonism spectrum from Parkinson’s disease from atypical parkinsonism, ensuring timely and accurate diagnoses for improved patient outcomes.
•  Apply current evidence-based treatments in the management of movement disorders,  including pharmacologic advancements and non-pharmacologic interventions, to enhance  individualized patient care.
•  Demonstrate competence in device-based therapies, including Deep Brain Stimulation  (DBS) programming and neuro-anatomy as well as subcutaneous pump management, through didactic sessions as well as hands-on workshops designed to improve procedural skills and patient outcomes.
•  Identify and address hyperkinetic movement disorders by applying the latest treatment  approaches, enhancing quality of life for patients experiencing these conditions.
•  Enhance strategies for managing atypical presentations of movement disorders, using  evidence-based approaches to refine diagnostic and treatment approaches.
•  Increase confidence in interpreting neuro imaging in movement disorders to ensure APPs are given appropriate instruction in differentiating various findings consistent with Parkinson’s disease, atypical parkinsonisms, NPH, infections.

Disclosure of Relevant Financial Relationships

Parkinson and Movement Disorder Alliance (PMD Alliance) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  PMD Alliance is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

Zoltan Mari

• Site investigator for research/trial supported by AbbVie, Neuron23, AskBio, and Amneal.
• Speakers’ Bureau, consultant, and/or advisory board member for AbbVie, Amneal, Acadia, and Biogen.

Alexis C Gumble

• Speakers’ Bureau, consultant, and/or advisory board member for Amneal.

Alexis Santangelo

• Speakers’ Bureau, consultant, and/or advisory board member for Amneal and Supernus.

Arita McCoy

• Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America.

Cheryl Kyinn

• Speakers’ Bureau, consultant, and/or advisory board member for Acadia, Amneal, Abbvie, and Supernus. 

Christa Cooper

• Site investigator for research/trial supported by Roche.
• Speakers’ Bureau, consultant, and/or advisory board member for Teva, Neurocrine, and Abbott.

Clarisse Goas

• Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America.

Jessica Karl

• No disclosures to report.

Joan Miravite

• Speakers’ Bureau, consultant, and/or advisory board member for Medtronic and Abbott.

Kathy Huynh

• Speakers’ Bureau, consultant, and/or advisory board member for Medtronic and Boston Scientific. 

Katie Henke

• No disclosures to report.

Kinsey McCartney

• Speakers’ Bureau, consultant, and/or advisory board member for AbbVie.

Leonardo Brito de Almeida

• Speakers’ Bureau, consultant, and/or advisory board member for Medtronic and Boston Scientific. 

Maria Cristina Ospina

• Site investigator for research/trial supported by Inhibikase.
• Speakers’ Bureau, consultant, and/or advisory board member for Abbvie, Amneal, Neurocrine, Kyowa, Supernus, Teva, Merz, and Abbott.

Meredith Hatcher

• Speakers’ Bureau, consultant, and/or advisory board member for Abbvie, Merz, Abbott, Medtronic, Supernus, and Amneal.

Monica Volz

• Speakers’ Bureau, consultant, and/or advisory board member for Medtronic and Boston Scientific. 

Orla McQuade

• No disclosures to report.

Pam Zeilman

• Speakers’ Bureau, consultant, and/or advisory board member for Medtronic.

Patricia Clark

• No disclosures to report.

Ray Dorsey

• Site investigator for research/trial supported by Averitas Pharma, Biogen, Pfizer, Photopharmics, and Roche.
• Speakers’ Bureau, consultant, and/or advisory board member for Abbott, Abbvie, Acadia, Advarra, Aspen Neuroscience, Inc., Bial Pharmaceuticals, Biogen, Biohaven Pharmaceuticals, BioSensics, Boehringer Ingelheim, and Caraway Therapeutics.

Traci Hornbeck

• Speakers’ Bureau, consultant, and/or advisory board member for Boston Scientific.

Planners reported the following relevant financial relationships with ineligible entities related to the educational content of this CME activity:

Alexis Santangelo

• Speakers’ Bureau, consultant, and/or advisory board member for Amneal and Supernus.

Andrew Imbus

• Speakers’ Bureau, consultant, and/or advisory board member for Abbott.

Clarisse Goas

• Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America.

Erin Zinn

• Speakers’ Bureau, consultant, and/or advisory board member for Mitsubishi Tanabe Pharma America and Supernus.

Kettia Alusma-Hibbert

• No disclosures to report.

Mara McCrossin

• No disclosures to report.

Orla McQuade

• No disclosures to report.

Pam Zeilman

• Speakers’ Bureau, consultant, and/or advisory board member for Medtronic.

Jason Rivera

• No disclosures to report.

All identified relevant financial relationships are thoroughly vetted and mitigated according to PMD Alliance CME Program standard operating procedures. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA.  The planners of this activity do not recommend the use of any agent outside of the labeled indications.  The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Commercial Support

This activity is supported by independent medical education grants from Acadia.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development.  The information presented in this activity is not meant to serve as a guideline for patient management.  Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Request for Credit

In order to obtain your CME certificate, please follow the directions provided at the conclusion of the course.  

If you have questions regarding the certification of this activity, please contact PMD Alliance at education@pmdalliance.org